Description
A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from nasopharyngeal swab specimens.
- Sensitivity and Specificity
- COVID-19 – Sensitivity 93.9%, Specificity 100%
- Flu A – Sensitivity 91.4%, Specificity 95.7%
- Flu B – Sensitivity 87.6%, Specificity 95.9%
- FDA Emergency Use Authorization (EUA)
- Health Canada Approved
- Visually read in 15 minutes
- Flocked nasopharyngeal swab for superior specimen collection and patient comfort
